Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    100.0%

    Based on 3 completed trials

    Completion Rate
    100%(3/3)
    Active Trials
    0(0%)
    Results Posted
    100%(3 trials)

    Phase Distribution

    Phase 1
    2
    67%
    Phase 2
    1
    33%

    Phase Distribution

    2

    Early Stage

    1

    Mid Stage

    0

    Late Stage

    Phase Distribution3 total trials
    Phase 1Safety & dosage
    2(66.7%)
    Phase 2Efficacy & side effects
    1(33.3%)

    Highest Phase Reached

    Phase 2

    Trial Status & Enrollment

    Completion Rate

    100.0%

    3 of 3 finished

    Non-Completion Rate

    0.0%

    0 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    3

    all time

    Status Distribution
    Completed(3)

    Detailed Status

    Completed3

    Development Timeline

    Analytics

    Development Status

    Total Trials
    3
    Active
    0
    Success Rate
    100.0%
    Most Advanced
    Phase 2

    Trials by Phase

    Phase 12 (66.7%)
    Phase 21 (33.3%)

    Trials by Status

    completed3100%

    Recent Activity

    0 active trials
    Showing 3 of 3
    completedphase_2

    A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and Microalbuminuria

    NCT02332824
    completedphase_1

    Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participants With Renal or Hepatic Impairment

    NCT02367872
    completedphase_1

    Drug-Drug Interaction Study Between TAK-272 and Itraconazole, Digoxin or Midazolam

    NCT02370615

    Clinical Trials (3)

    Showing 3 of 3 trials
    NCT02332824Phase 2

    A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and Microalbuminuria

    Completed
    NCT02367872Phase 1

    Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participants With Renal or Hepatic Impairment

    Completed
    NCT02370615Phase 1

    Drug-Drug Interaction Study Between TAK-272 and Itraconazole, Digoxin or Midazolam

    Completed

    All 3 trials loaded

    Drug Details

    Intervention Type
    Drug
    Total Trials
    3